Recurrent loss or other inactivation of PTPRD has been detected in different human malignancies16–21, and one-copy loss of PTPRD has also been oncogenic in p16Ink4a knockout RCAS PDGFB/Nestin-tvA glioma mouse model16. This evidence concerns the gene NES and central nervous system cancer.